366789-59-5

Upstream product

• 121238-27-5 2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl trichloroimidate 
• 366789-55-1 (3R/S)-3-(tert-butyldiphenylsilyl)oxymethyl-6-hydroxy-1-(5',6',7'-trimethoxyindol-2'-yl-carbonyl)-2,3-dihydro-1H-indole 
• 128781-07-7 5,6,7-trimethoxy-1H-indole-2-carboxylic acid 
• 366789-52-8 6-benzyloxy-3-hydroxymethyl-2,3-dihydro-1H-indole 
• 173368-77-9 6-benzyloxy-3-hydroxymethyl-N-methanesulfonyl-2,3-dihydro-1H-indole 
• 366789-54-0 (3R/S)-6-benzyloxy-3-(tert-butyldiphenylsilyl)oxymethyl-1-(5',6',7'-trimethoxyindol-2'-yl-carbonyl)-2,3-dihydro-1H-indole 
• 366789-53-9 (3R/S)-6-benzyloxy-3-hydroxymethyl-1-(5',6',7'-trimethoxyindol-2'-yl-carbonyl)-2,3-dihydro-1H-indole 

Relevant academic research and scientific papers

A strategy for tumor-selective chemotherapy by enzymatic liberation of seco-duocarmycin SA-derivatives from nontoxic prodrugs

Immuno-conjugates obtained by linking enzymes with appropriate monoclonal antibodies, which bind to tumor-associated antigens, can be employed in a tumor-selective antibody directed enzyme prodrug therapy (ADEPT). For this strategy the glycosides 17a-c we